Skip to content

Author

Muhammad Roshaan

We have 2 of 10 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Dose-response efficacy and safety of the aldosterone synthase inhibitor baxdrostat in resistant hypertension: a systematic review and network meta-analysis.

Baxdrostat 1 mg and 2 mg significantly increased overall adverse events and hyperkalemia, whereas serious adverse events were not significantly increased, and both higher doses significantly increased hyperkalemia risk.

M. Shahzaib, Hafsa Ali, Muhammad Roshaan et al. · 0 citations
Review Jul 2026

Efficacy and Safety of Rivaroxaban in Patients with Peripheral Artery Disease: A GRADE-assessed Systematic Review and Meta-Analysis.

Findings support individualized use of rivaroxaban-based therapy in carefully selected patients, balancing ischemic and limb-protective benefits against bleeding risk, and support individualized use of rivaroxaban-based therapy in carefully selected patients.

M. Shahzaib, Muhammad Roshaan, M. K. Buhadur Ali et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.